FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	ırden
houre por roeponeo	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(IIII OI I y	pe Response:	s)													
Name and Address of Reporting Person * Katkin Keith				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner				
C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/15/2020							Officer (give	e title below)	Other (specify below)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deri	vative Securitie	s Acquired	l, Disposed	of, or Bene	ficially Owned		
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)		on D	ate, if C		8) (1	A) or Disposed on nstr. 3, 4 and 5) (A) or mount (D)	of (D) Ow Tra		Securities Being Reported	d Ov Fo Di or (I)	vnership rm: Be rect (D) Ov	Nature Indirect neficial vnership str. 4)
	•	separate line for eacl		· Derivati	ive S	ecurities	Acqı	Person in this display	s who respond form are not rest a currently was seed of, or Bene nvertible secur	equired to valid OME eficially Ow	respond control r	unless the		d SEC 147	(4 (9-02)
1. Title of Derivative	Conversion		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code		5. Numb				7. Title and Amount of Underlying Securities (Instr. 3 and 4)					
Security (Instr. 3)	or Exercise Price of Derivative		Execution Date, if any	Transac Code	tion		ative s d (A) sed	6. Date Exe Expiration (Month/Day		of Underly Securities	ying		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirec Beneficial Ownershi (Instr. 4)
	or Exercise Price of Derivative	Date	Execution Date, if any	Transac Code	tion	of Deriva Securitie Acquired or Dispo- of (D) (Instr. 3,	ative s l (A) sed 4,	Expiration	Date y/Year) Expiration	of Underly Securities	ying	Derivative Security	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Katkin Keith C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/15/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.